Wang Na, Fu Jianjiang, Li Zhihua, Jiang Ningni, Chen Yanhong, Peng Juan
Department of Pathology, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.
The Third Clinical School, Guangzhou Medical University, Guangzhou 510150, China.
Cancers (Basel). 2022 Feb 5;14(3):811. doi: 10.3390/cancers14030811.
Given that 3-phosphoinositide-dependent kinase 1 (PDK1) plays a crucial role in the malignant biological behaviors of a wide range of cancers, we review the influence of PDK1 in breast cancer (BC). First, we describe the power of PDK1 in cellular behaviors and characterize the interaction networks of PDK1. Then, we establish the roles of PDK1 in carcinogenesis, growth and survival, metastasis, and chemoresistance in BC cells. More importantly, we sort the current preclinical or clinical trials of PDK1-targeted therapy in BC and find that, even though no selective PDK1 inhibitor is currently available for BC therapy, the combination trials of PDK1-targeted therapy and other agents have provided some benefit. Thus, there is increasing anticipation that PDK1-targeted therapy will have its space in future therapeutic approaches related to BC, and we hope the novel approaches of targeted therapy will be conducive to ameliorating the dismal prognosis of BC patients.
鉴于3-磷酸肌醇依赖性激酶1（PDK1）在多种癌症的恶性生物学行为中起关键作用，我们综述了PDK1对乳腺癌（BC）的影响。首先，我们描述了PDK1在细胞行为中的作用，并对PDK1的相互作用网络进行了表征。然后，我们确立了PDK1在BC细胞的致癌作用、生长与存活、转移及化疗耐药性中的作用。更重要的是，我们梳理了目前针对BC的PDK1靶向治疗的临床前或临床试验，发现尽管目前尚无用于BC治疗的选择性PDK1抑制剂，但PDK1靶向治疗与其他药物的联合试验已带来了一些益处。因此，人们越来越期待PDK1靶向治疗在未来与BC相关的治疗方法中占有一席之地，并且我们希望新型靶向治疗方法将有助于改善BC患者的不良预后。
